CURE’s prostate cancer page is an extensive resource of cancer information featuring the latest prostate cancer news, expert oncologist insights on the latest cancer treatments, oncology research, advocacy efforts, and medical data on prostate cancer.
June 13th 2025
Surgery and radiation yield similar cancer outcomes for low-risk prostate cancer, but higher-risk cases may require combining treatments, experts said.
Prostate Cancer Foundation's Robust Collection of New Patient Resources Now Available
May 13th 2019The Prostate Cancer Foundation announced the newly revised 2019 Prostate Cancer Patient Guide, a comprehensive resource for diagnosis, treatment, side effects, survivorship, and risk factors for patients and families with a history of prostate cancer.
Erleada Improves Survival in Prostate Cancer Subset
February 1st 2019In topline findings from the phase 3 TITAN trial (NCT02489318) announced today by Janssen, Erleada (apalutamide) in combination with androgen deprivation therapy (ADT) significantly improved radiographic progression-free survival (rPFS) and overall survival (OS) versus placebo in patients with metastatic castration-sensitive prostate cancer.
Aggressive Radiation Therapy Improves Survival in Patients with Metastatic Cancer
October 23rd 2018A high dose of precision radiation could drastically increase the survival rates of patients with metastatic cancer, and double the time patients live without cancer growth, according to study results presented at the 60th Annual Meeting of the American Society for Radiation Oncology.
Rubraca Granted Breakthrough Designation for Prostate Cancer
October 2nd 2018The FDA has granted the PARP inhibitor Rubraca (rucaparib) a breakthrough therapy designation for single-agent use in adult patients with BRCA1/2-positive metastatic castration-resistant prostate cancer (mCRPC) following at least one androgen receptor–directed therapy and taxane-based chemotherapy.